Breast Cancer
Conditions
Keywords
Artificial intelligence
Brief summary
The purpose of this observational study is to assess whether the use of AI (Transpara®) can lead to an improved quality of a double reading mammography screening program. This is investigated by performing AI as a third reader and as a decision support during the consensus meeting, compared with conventional mammography screening (double reading and consensus without AI).
Detailed description
The AI cancer detection system will act as a 3rd reader and will recall additional cases to the consensus conference: the exams that were not recalled by double reading but are classified as the 3% most suspicious exams, based on AI derived cancer-risk scores. Secondly, AI is used as a decision support during consensus. AI risk scores and Computer-Aided Detection (CAD)-marks of suspicious calcifications and soft tissue lesions are provided to the reader(s). The hypothesis of this study is that the use of AI has the potential to improve the quality of the screening program by increasing the cancer detection rate without affecting the recall rate.
Interventions
The use of AI as a third reader and as a decision support system during consensus meeting
Sponsors
Ostergotland County Council, Sweden
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
* Women participating in the regular Breast Cancer Screening Program in Region Östergötland Linkoping
Exclusion criteria
* Women with breast implants or other foreign implants in the mammogram * Women with symptoms or signs of suspected breast cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cancer Detection rate | After 4 months of inclusion | Proportion of women diagnosed with breast cancer among those recalled after consensus |
| Recall or referral rate | After 4 months of inclusion | Proportion of women who are referred for further diagnostic workup after consensus |
| Positive predictive value of referrals | After 4 months of inclusion | Proportion of women diagnosed with breast cancer among those referred |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Positive predictive value of Transpara® scores | After 4 months of inclusion | Proportion of breast cancers diagnosed among women with a given AI score |
Countries
Sweden
Outcome results
None listed